Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01647711
Title A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

lung non-small cell carcinoma

Therapies

Afatinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.